Evercore ISI Group Maintains Outperform on Atea Pharmaceuticals, Raises Price Target to $10
Evercore ISI Group analyst Jonathan Miller maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Outperform and raises the price target from $6 to $10.
Login to comment